A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419 ·Status: COMPLETED ·Phase: PHASE2

A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.

NCT02068196 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

NCT03199846 ·Status: COMPLETED

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France

NCT04550247 ·Status: ACTIVE_NOT_RECRUITING

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

NCT02905266 ·Status: COMPLETED ·Phase: PHASE3

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162 ·Status: TERMINATED ·Phase: PHASE2

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168 ·Status: COMPLETED ·Phase: PHASE3

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045 ·Status: TERMINATED ·Phase: PHASE2

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

NCT00942162 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab + Temozolomide in Metastatic Melanoma

NCT01119508 ·Status: COMPLETED ·Phase: PHASE2

A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

NCT03165422 ·Status: COMPLETED

Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

NCT00495066 ·Status: NO_LONGER_AVAILABLE

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

NCT05115006 ·Status: COMPLETED

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

NCT01245556 ·Status: COMPLETED ·Phase: PHASE1

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

NCT03949153 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

NCT02320058 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

NCT03978611 ·Status: TERMINATED ·Phase: PHASE1

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533 ·Status: TERMINATED ·Phase: PHASE3

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

NCT01213472 ·Status: COMPLETED ·Phase: PHASE1

PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma

NCT02492815 ·Status: COMPLETED

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

NCT06566391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2